As hurricane season begins, the weather agency is seeing promise in drones and other emerging plane-deployed technologies.

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

Knowledge is power, so here’s how to find power-gobbling data centers near you. Knowledge is power, so here’s how to find power-gobbling data centers near you. is a policy reporter at The Verge ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

Florida-Based AP Governance Firm Selected as RFP-Stage Contender, Reinforcing Its Authority in Enterprise SAP Vendor Master Data Compliance and Modernization PORT ST. LUCIE, Fla., May 10, 2026 / PRZen ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

Developers of the proposed data center along W.Va. 62 north of Point Pleasant, West Virginia, have submitted their application for a construction permit to the West Virginia Department of ...

As global temperatures rise, data centers for artificial intelligence are creating “heat islands” that could have significant impacts on communities and their surrounding environments in the years to ...

A new holographic storage technique uses light in three dimensions to dramatically increase how much data can be stored. It encodes information throughout a material using amplitude, phase, and ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

An analyst named the death of a patient as a potential explanation for the stock drop. (Lynn Fenn/iStock/Getty Images Plus) Erasca has backed up bullish claims about its pan-RAS drug having a ...